



## Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience's 49th Annual Scientific Meeting on October 23, 2019

October 7, 2019

CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 7, 2019-- [Lineage Cell Therapeutics, Inc.](#) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, will serve as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company's Vision Restoration Program at [Neuroscience 2019](#), the Society for Neuroscience's 49<sup>th</sup> Annual Scientific Meeting, to be held at the McCormick Center in Chicago, IL (October 19-23, 2019). The presentation, entitled "*Transplantation of human embryonic stem cell derived retinal sheets improves vision in immunodeficient rats with retinal degeneration*," will be presented as part of the Neural Differentiation, Transplantation and Regeneration Session on Wednesday, October 23<sup>rd</sup>, 2019 at 8:00 am Eastern Time in room S505 (Session #626).

Guided by its mission and its values, the vision of the [Society for Neuroscience](#) (SfN) is to advance breakthrough discoveries in neuroscience and promote innovative translation of scientific advances to improve the health of people everywhere. The SfN's 49<sup>th</sup> annual meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers, explore new tools and technologies, and advance careers. For more information, please visit <https://www.sfn.org/Meetings/Neuroscience-2019> or follow the SfN on Twitter [@SfNtweets](#).

### About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical assets include (i) OpRegen<sup>®</sup>, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia<sup>®</sup>, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit [www.lineagecell.com](http://www.lineagecell.com) or follow the Company on Twitter [@LineageCell](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191007005237/en/>

Source: Lineage Cell Therapeutics, Inc.

### Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone  
([ir@lineagecell.com](mailto:ir@lineagecell.com))  
(510) 871-4188

### Solebury Trout IR

Gitanjali Jain Ogawa  
([Gogawa@troutgroup.com](mailto:Gogawa@troutgroup.com))  
(646) 378-2949